Please login to the form below

Not currently logged in
Email:
Password:

Merck collaborate over betrixaban

Merck and Portola Pharmaceuticals have signed an exclusive global collaboration and license agreement for betrixaban

Global research-driven pharmaceutical company, Merck & Co, and Portola Pharmaceuticals have signed an exclusive global collaboration and license agreement for the development and commercialisation of betrixaban, an investigational oral Factor Xa inhibitor anticoagulant currently in phase II clinical development for the prevention of stroke in patients with atrial fibrillation (SPAF).

In return for an exclusive worldwide license to betrixaban, Merck will pay Portola an initial fee of $50m. Portola is also eligible to receive additional cash payments amounting to $420m on achievement of certain development, regulatory and commercialisation milestones, as well as double-digit royalties on worldwide sales of betrixaban, if approved. Merck will assume all development and commercialisation costs, including the costs of phase III clinical trials, however, Portola has retained an option to co-fund phase III clinical trials in return for additional royalties and to co-promote betrixaban with Merck in the US.

According to Dr Luciano Rossetti, senior vice president and franchise head, atherosclerosis and cardiovascular at Merck Research Laboratories: "This agreement reinforces Merck's focus on developing an innovative portfolio of products for the treatment and management of multiple aspects of cardiovascular disease."

13th July 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics